Nancy Squires, MD
Family Medicine · Dagsboro, DENPI 1841299906
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 33.3% of the total. Reporting peaked in 2019 at $1,107 and has fallen 70.3% since, to $329 in 2025.
Across 206 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$505
- GSK$360
- Boehringer Ingelheim$340
- Amgen$280
- Astellas Pharma US Inc$275
- plus $1K from 17 others
What the payments were for
- Consulting fees$200%
- Speaking & faculty fees$2004%
- Food & beverage$4,50393%
- Education$1012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,606 |
| Novo Nordisk | 32 | $505 |
| GSK | 18 | $360 |
| Boehringer Ingelheim | 20 | $340 |
| Amgen | 12 | $280 |
| Astellas Pharma US Inc | 11 | $275 |
| Lilly USA, LLC | 15 | $238 |
| Roche Molecular Systems, Inc. | 1 | $200 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Organogenesis Inc. | 1 | $118 |
| AbbVie(2 entities) | 6 | $97 |
| Merck | 6 | $91 |
| Smith+Nephew | 1 | $90 |
| Pfizer | 5 | $70 |
| Novartis | 3 | $70 |
| Amarin Pharma, Inc. | 4 | $64 |
| Kowa Pharmaceuticals America, Inc. | 4 | $63 |
| Sunovion Pharmaceuticals Inc. | 3 | $59 |
| Bayer | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 1 | $40 |
| Johnson & Johnson | 2 | $36 |
| Dexcom, Inc. | 1 | $25 |
| Dynavax Technologies Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,824 in reported general payments places this provider in the 85th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 128 | $184,088 |
| OzempicSemaglutide | 85 | $174,502 |
| JardianceEmpagliflozin | 74 | $83,095 |
| EliquisApixaban | 51 | $75,353 |
| XareltoRivaroxaban | 45 | $69,608 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $52,170 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $42,271 |
| TrulicityDulaglutide | 18 | $40,632 |
| JanuviaSitagliptin Phosphate | 23 | $37,578 |
| MounjaroTirzepatide | 24 | $36,358 |
| LinzessLinaclotide | 25 | $34,514 |
| EntrestoSacubitril/Valsartan | 16 | $29,712 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $24,172 |
| Bydureon BciseExenatide Microspheres | 16 | $21,104 |
| RybelsusSemaglutide | 11 | $20,321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,606 | $208,260143 claims |
| Novo NordiskOzempic, Rybelsus | $505 | $194,82396 claims |
| Boehringer IngelheimJardiance | $340 | $83,09574 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $238 | $76,99042 claims |
| PfizerEliquis | $70 | $75,35351 claims |
| Johnson & JohnsonXarelto | $36 | $69,60845 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $360 | $56,50639 claims |
| AbbVieLinzess, Savella, Synthroid | $97 | $43,224132 claims |
| MerckJanuvia | $91 | $37,57823 claims |
| NovartisEntresto | $70 | $29,71216 claims |
| Astellas Pharma US IncMyrbetriq | $275 | $17,71416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 352 family medicine providers in Delaware.
Other family medicine in Dagsboro
- Gregory PapaNew Castle$67K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Wayne TuckerBear$20K
- Ian MyersNewark$17K
- Glenn HamiltonWilmington$17K
- Dustin DavisGeorgetown$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.